MITRAL VALVE PATHOLOGY IN CONNECTIVE TISSUE DYSPLASIA
https://doi.org/10.15829/1560-4071-2016-11-81-86
Abstract
Recently, the main cause of mortality and disability in the world are cardiovascular diseases. By the data from autopsies, valve defects have 4-7% prevalence, and most common are mitral valve defects. Valve prolapse is caused by in-born defect of connective tissue development. Reconstruction surgery continue becoming more common in mitral regurgitation (MR) correction and is more preferable than the valve replacement. Regardless the long history of successful management of MR, official data from most world cardiosurgery centers shows than reconstruction operations are done just in 10-20% cases. Issues on the improvement of the management of patients with connective tissue dysplasia are still open. There is enough literature on laboratory and experimental studies showing benefits and disadvantages of one or other methods, but there are no large clinical trials with sufficient evidence, to confirm or stronly deny differences in clinical outcomes depending on the selection of one or other method.
About the Authors
A. V. Bogachev-Prokofiev
E. N. Meshalkin Novosibirsk Scientific-Research Institute of Circulation Pathology, Novosibirsk, Russia
Russian Federation
Russian Federation
A. V. Afanasiev
E. N. Meshalkin Novosibirsk Scientific-Research Institute of Circulation Pathology, Novosibirsk, Russia
Russian Federation
Russian Federation
I. Yu. Zhuravleva
E. N. Meshalkin Novosibirsk Scientific-Research Institute of Circulation Pathology, Novosibirsk, Russia
Russian Federation
Russian Federation
D. P. Demidov
E. N. Meshalkin Novosibirsk Scientific-Research Institute of Circulation Pathology, Novosibirsk, Russia
Russian Federation
Russian Federation
S. I. Zheleznev
E. N. Meshalkin Novosibirsk Scientific-Research Institute of Circulation Pathology, Novosibirsk, Russia
Russian Federation
Russian Federation
O. Yu. Malakhova
E. N. Meshalkin Novosibirsk Scientific-Research Institute of Circulation Pathology, Novosibirsk, Russia
Russian Federation
Russian Federation
Ya. V. Syrtseva
E. N. Meshalkin Novosibirsk Scientific-Research Institute of Circulation Pathology, Novosibirsk, Russia
Russian Federation
Russian Federation
A. M. Karaskov
E. N. Meshalkin Novosibirsk Scientific-Research Institute of Circulation Pathology, Novosibirsk, Russia
Russian Federation
Russian Federation
References
1. Carpentier A, Adams D, Filsoufi F. Carpentier’s reconstructive valve surgery. 2010. Saunders: Philadelphia. 268 p.
2. Marchenko SP. Reconstructive surgery of the atrioventricular valves of the heart: author. dis. Dr. med.Sciences. SPb., 2008. 49. Russian (Марченко С. П. Реконструктивная хирургия атриовентрикулярных клапанов сердца: автореф. дис. д. м.н. Спб., 2008. 49).
3. Marchenko SP, Shahverdiev NN, Khubulava GG. Problem of reconstructive surgery of the atrioventricular valves of the heart. Vestnik of Russian military medical Academy. 2008; 2: 160-4. Russian (Марченко С. П. Проблема реконструктивной хирургии атриовентрикулярных клапанов сердца. Марченко С. П., Шихвердиев Н. Н., Хубулава Г. Г. Вестник Российской военно-медицинской академии. 2008; 2: 160-4).
4. Skopin II, Danilov VG. Current status reconstructive surgery of the mitral valve correction of degenerative mitral regurgitation (morphology, indications for correction, the overall results of reconstructive operations). Thoracic and cardiovascular surgery. 2013; 4: 16-23. Russian (Скопин И. И., Данилов Г. В. Современное состояние реконструктивной хирургии митрального клапана коррекция дегенеративной митральной недостаточности (морфология, показания к коррекции, общие результаты реконструктивных операций). Грудная и сердечно-сосудистая хирургия. 2013; 4: 16-23).
5. Adams DH, Rosenhek R, Falk V. Degenerative mitral valve regurgitation: best practice revolution. European heart journal. 2010; 31: 1958-67.
6. Chikwe J, Adams DH. State of the Art: Degenerative Mitral Valve Disease. Heart, Lung and Circulation 2009; 18: 319-29.
7. Anyanwu AC, Adams DH. Etiologic classification of degenerative mitral valve disease: Barlow’s disease and fibroelastic deficiency. Thorac and cardiovasc surg. 2007; 19: 90-6.
8. De Bonis M, Lapenna E, Alfieri O. Edge-to-edge Alfieri technique for mitral valve repair: which indications? Curr Opin Cardiol. 2013 Mar; 28(2): 152-7.
9. Borger MA, Mohr FW. Repair of Bileaflet Prolapse in Barlow Syndrome. Semin Thoracic Surg. 2010; 22: 174-8.
10. Marchenko SP, Shahverdiev NN, Khubulava GG. Morphology of the atrioventricular valves as the basis for the operation. Pathology of blood circulation and cardiac surgery. 2008; 4: 24-30. Russian (Марченко С. П., Шихвердиев Н. Н., Хубулава Г. Г. Морфология атриовентрикулярных клапанов как основа выполнения реконструктивных операций. Патология кровообращения и кардиохирургия. 2008; 4: 24-30).
11. Flameng W, Meuris B, Herijgers P, et al. Durability of mitral valve repair in Barlow disease versus fibroelastic deficiency. J Thorac Cardiovasc Surg 2008; 135: 274-82.
12. Evtushenko AV, Evtushenko VV, Petlin KA, et al. Use of resection and reresection technologies in reconstructive surgery of the mitral valve. Thoracic and cardiovascular surgery. 2011; 4: 27-9. Russian. (Евтушенко А. В., Евтушенко В. В., Петлин К. А. и др. Использование резекционных и нерезекционных технологий в реконструктивной хирургии митрального клапана. Грудная и сердечно-сосудистая хирургия. 2011; 4: 27-9).
13. Filsoufi F, Carpentier A. Principles of reconstructive surgery in degenerative mitral valve disease. Sem in thorac and cardiovasc surg. 2007; 19(2), 103-10.
14. Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. J Am Coll Cardiol 2008; 52: e1-e142.
15. Camm AJ, Lip GYH, De Caterina R, et al. Guidelines on the management of valvular heart disease (version 2012): Eur Heart J. 2012; 33(19): 2451-96.
16. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: A report of the American college of cardiology/ American heart association task force on practice guidelines. J Am Coll Cardiol. 2014; 63(22). doi:10.1016/j.jacc.2014.02.536.
17. Enriquez-Sarano M, Akins CW, Vahanian A. Mitral regurgitation. Lancet 2009; 373: 1382-94.
18. Ling LH, Enriquez-Sarano M, Seward JB, et al. Clinical outcome of mitral regurgitation due to flail leaflet. N Engl J Med 1996; 335: 1417-23.
19. Hueb AC, Jatene FB, Moreira LF, et al. Ventricular remodelling and mitral valve modifications in dilated cardiomyopathy: new insights from anatomic study. J Thorac Cardiovasc Surg. 2002; 124: 1216-24.
20. Galloway AC, Grossi EA, Bizekis CS, et al. Evolving techniques for mitral valve reconstruction. AnnSurg 2002; 236: 288-94.
21. Kang DH, Kim JH, Rim JH, et al. Comparison of early surgery versus conventional treatment in asymptomatic severe mitral regurgitation. Circulation 2009; 119: 797-804.
22. Rosenhek R, Rader F, Klaar U, et al. Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation 2006; 113: 2238-44.
23. Tribouilloy C, Grigioni F, Avierinos JF, et al. Survival implication of left ventricular endsystolic diameter in mitral regurgitation due to flail leaflets: a long-term follow-up multicenter study. J Am Coll Cardiol 2009; 54: 1961-8.
24. Pizarro R, Bazzino OO, Oberti PF, et al. Prospective validation of the prognostic usefulness of brain natriuretic peptide in asymptomatic patients with chronic severe mitral regurgitation. J Am Coll Cardiol 2009; 54: 1099-106.
Review
For citations:
Bogachev-Prokofiev A.V., Afanasiev A.V., Zhuravleva I.Yu., Demidov D.P., Zheleznev S.I., Malakhova O.Yu., Syrtseva Ya.V., Karaskov A.M. MITRAL VALVE PATHOLOGY IN CONNECTIVE TISSUE DYSPLASIA. Russian Journal of Cardiology. 2016;(11):81-86. (In Russ.) https://doi.org/10.15829/1560-4071-2016-11-81-86
Views:
4198
Email this article 